key: cord-0688489-8w350118
authors: Jakhar, Deepak; Sah, Neha; Kaul, Subuhi
title: Injection site reactions associated with the use of Mycobacterium w in COVID‐19 patients
date: 2022-02-27
journal: Int J Dermatol
DOI: 10.1111/ijd.16104
sha: 756c7c117873bdcf12c2cebcaca276ce706bacd2
doc_id: 688489
cord_uid: 8w350118

nan

Injection site reactions associated with the use of Mycobacterium w in COVID-19 patients Dear Editor,

In an attempt to mitigate the severity of the disease, several medications have been used in patients with COVID-19 (coronavirus disease 2019). 1 One such therapy is intradermal Mycobacterium w (Mw), which has been used in COVID-19 patients as an immunomodulatory agent. 1 A randomized trial on 42 patients demonstrated that the use of Mw in addition to standard care resulted in early clinical improvement compared to standard care alone in patients with severe COVID-19. 2 There were no cutaneous adverse reactions reported in this study. However, we encountered two cases of COVID-19 that developed local reactions to intradermal injection of Mw and intend to describe these cases so physicians can be aware of such cutaneous reactions. This report aims to highlight the adverse effects that can arise with the use of this exploratory therapy in COVID-19 patients. It is important to ask about the history of intradermal injections if one encounters such lesions and recognize that no specific treatment is required as these lesions subside on their own. To conclude, when presented with unusual skin lesions in COVID-19 patients, physicians should consider COVID-19 therapy-related cutaneous reactions apart from the varying COVID-19 disease-related skin manifestations that have been described in literature. 7 

Safety of an immunomodulator Mycobacterium w in COVID-19

A randomised trial of Mycobacterium w in critically ill patients with COVID-19: ARMY-1

A clinical trial of Mycobacterium w in critically ill COVID 19 patients

Field trials on the use of Mycobacterium w vaccine in conjunction with multidrug therapy in leprosy patients for immunotherapeutic and immunoprophylactic purposes

Efficacy and safety of Mycobacterium indicus pranii as an adjunct therapy in category II pulmonary tuberculosis in a randomized trial

Mycobacterium W. -an unusual side effect

Classification of the cutaneous manifestations of COVID-19: a rapid prospective nationwide consensus study in Spain with 375 cases